Literature DB >> 1245092

Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women.

P T Männistö.   

Abstract

The pharmacokinetics of oral nalidixic acid (NA, 1 gm 4 times a day) and oxolinic acid (OA, 750 mg 2 times a day) administered for 7 days were studied in the same 10 healthy women on the first, third, and seventh days of the treatment. The peak concentrations of NA + OH-NA (hydroxynalidixinic acid) in serum at 2 to 3 hr were 34 mug/ml (total) and 23 mug/ml (unconjugated) on the first day and nearly two times higher on the third and seventh days; 82% to 85% of these amounts were NA. The protein-free fraction of NA + OH-NA was 8.8% to 18.3%. The total concentration of NA + OH-NA in urine was 1,220 to 2,700 mug/ml, the unconjugated concentration, 250 to 350 mug/ml, and the chemotherapeutically active concentration, 55 to 75 mug/ml. In steady state the 24-hr recovery of the total drug was 79% of the daily dose. The excretion rate in urine was 591 to 853 mg/6 hr. The OA concentration in serum was very low on the first day of the treatment, but increased to 4- to 5-fold on the third and seventh days: 6.2 to 6.4 mug/ml (total) and 3.3 to 3.6 mug/ml (unconjugated). The protein-free OA represented 19% to 23% of the total amount. The modest initial serum concentrations of OA were confirmed by the low urine concentrations on the first day. In steady state the OA concentration in urine was 570 mug/ml (total) and 35 mug/ml (unconjugated), and the 24-hr recovery, 49% and 3%, respectively. The microbiologic assay gave somewhat higher concentrations of the active drug than did the chemical assay. When taken with food, the excretion of OA in urine was retarded by 6 hr but the 48-hr recovery was not decreased.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1245092     DOI: 10.1002/cpt197619137

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

Authors:  N Ferry; N Bernard; N Pozet; E Gardes; M Bruguier; G Cuisinaud; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

2.  The place of quinolones in antibacterial therapy in hospitals.

Authors:  R P Mouton
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

3.  Minimal inhibitory concentrations of 19 antimicrobial agents for 96 clinical isolates of group IVe bacteria.

Authors:  W D Welch; R K Porschen; B Luttrell
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

4.  Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.

Authors:  E Klinge; P T Männistö; R Mäntylä; J Mattila; U Hänninen
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment.

Authors:  T B Vree; M Van den Biggelaar-Martea; E W Van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-08-20

6.  Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans.

Authors:  T B Vree; M van den Biggelaar-Martea; E W van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-06-18

7.  Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).

Authors:  M S Sabbour; M A El Bokl; L M Osman
Journal:  Infection       Date:  1984 Nov-Dec       Impact factor: 3.553

8.  Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation.

Authors:  T B Vree; W J Wijnands; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1988-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.